Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT05374577
Active, not recruiting Observational

Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

NCT05374577 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Giessen
Phase
Observational
Started
2022-04-15
Last updated
2025-09-04

Condition(s) studied

COVID-19

Investigational drug(s) / intervention(s)

pulmonary vascular dysfunctionpulmonary vascular function

pulmonary vascular dysfunction: Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)

pulmonary vascular function: Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.

Study summary

To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome who present to our pneumology or infectious disease outpatient clinic or corresponding ward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation * Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection without post/long-COVID-19 syndrome who present to our post-infection outpatient clinic for follow-up Exclusion Criteria: * Patients who refuse to participate in the study * Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronic obstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease) that was diagnosed prior to acute COVID-19 disease and whose progression appears likely as the cause of dyspnea * Other non pneumologic causes of dyspnea (e.g., hemoglobin \< 100 g/L) * Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronary syndrome) * Inability to perform spiroergometry, including transient orthopedic problems, contraindications to central venous and arterial catheter placement (e.g., severe bleeding tendency).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Natascha Sommer Giessen Germany

More University of Giessen trials in Germany

Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure Recruiting
Combination of Ranibizumab and Targeted Laser Photocoagulation Active, not recruiting
Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension Recruiting
Giessen Pulmonary Hypertension in Lung Cancer Registry Recruiting
PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension Recruiting

Other trials for the same condition

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19 Active, not recruiting
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults Active, not recruiting
COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life Recruiting
Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project Recruiting
Post COVID-19 Condition Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05374577 on ClinicalTrials.gov ↗ ← All trials in Germany